In vivo CAR T: Faster, cheaper, and more effective cancer care
Dec 16, 2024 · Recent advancements in ex vivo CAR T-cell therapies have revolutionised cancer treatment by harnessing the power of a patient’s own immune system to recognise and fight cancer. Treatment outcomes for large B-cell lymphoma were dismal before CAR T-cell therapies. After two relapses, fewer than 30 percent of patients responded to treatment, and the median overall survival was less than seven ...
Drug Target Review: Leading Research & Insights in Drug Discovery
Stay at the forefront of drug discovery and therapeutic development with Drug Target Review. Dive into the latest research, industry analysis and technological advancements. Connect with world-renowned scientists and explore peer-reviewed articles, webinars, and more.
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
Jun 18, 2024 · Mike Holmes, PhD, Chief Scientific Officer at Tessera Therapeutics. Michael joined Tessera in December 2021 as Chief Scientific Officer. Dr Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases.
Establishing Alpha CETSA HT in primary screening - Drug Target …
Jun 23, 2020 · Using CETSA ® HT for compound screening and hit confirmation; Applying CETSA ® HT on targets that are lacking chemical starting points; Overcoming challenges when using CETSA ® HT in high-throughput screening; How CETSA ® HT enables protein degradation focused drug discovery projects, such as PROTACs.; KEYNOTE SPEAKERS. Julie Alexandre, Senior Research Scientist, Vertex Pharmaceutical
Drug candidates with blockbuster potential for CNS diseases
Sep 19, 2024 · Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam. Following successful interactions at the End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration (FDA) earlier this year we now look forward to the interactions with European drug regulatory authorities in the autumn for the start of a ...
Novel nasal spray effectively prevents influenza infection
Sep 25, 2024 · Cookie Type Duration Description; cookielawinfo-checkbox-advertising-targeting: persistent: 1 year: The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
Boltz-1: A new open-source AI tool for drug discovery
Dec 31, 2024 · MIT researchers have introduced Boltz-1, an open-source artificial intelligence (AI) model set to accelerate biomedical research and drug development. Developed by scientists at the MIT Jameel Clinic for Machine Learning in Health, Boltz-1 matches the performance of Google DeepMind’s AlphaFold3, which predicts the three-dimensional (3D) structures of proteins and other biological molecules.
Realising the promise of DNA vaccines and enabling genetic …
Apr 5, 2022 · Enjoying this article by Dr John Lewis? Then join him as well as Sijme Zeilemaker, CEO of Immunetune and Thomas Tillet, President & Co-Founder of MBF Therapeutics, at our Development of Next-Generation Vaccines Online Summit this June. They will be speaking during the panel discussion ‘The broad potential of DNA vaccines’ which will be moderated by Dr Gary McLean, Professor at London ...
Publications - Drug Target Review
From January 2024, we will be bidding farewell to the current Drug Target Review magazine and launching a series of innovative offerings for the upcoming year.. Topic-specific eBooks: Delve into key topics and hear more from our editor and industry leaders
SRP-001: redefining pain treatment with a safer, non-opioid …
Jul 1, 2024 · This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and neuropathic pain and migraines.